Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients

被引：0
|
作者：
S Lage
R Carvalho
L Kopel
M Ribeiro
J Bastos
A Fagundes Jr
H Araujo
C Strunz
P Garbes-Netto
机构：
[1] Heart Institute (Incor) University of São Paulo,
[2] Instituto BioChimico,undefined
来源：
Critical Care | / 10卷 / Suppl 1期
关键词：
Deep Vein Thrombosis; Enoxaparin; Prosthetic Valve; Sodium Enoxaparin; Critical Care Unit;
D O I：
10.1186/cc4508
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Sensitivity and specificity determined by receiver operating characteristcs (ROC) curve for anti-xa factor titration used as efficacy marker of enoxaparin in critically ill patients.
    Lage, Silvia G.
    Kopel, Liliane
    T Carvalho, Ricardo
    Ribeiro, Marcelo A.
    Bastos, Jaime F.
    Fagundes, Antonio P.
    Araujo, Helia B.
    Garbes-Netto, Pedro
    de Janeiro, Rio
    [J]. CRITICAL CARE MEDICINE, 2006, 34 (12) : A149 - A149
  • [2] Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients
    Vincent, Philippe D.
    Albert, Martin
    Champagne, Marie-Christine
    Zikos, Theodora
    Boulanger, Isabelle
    Blais, Lucie
    Williamson, David R.
    [J]. JOURNAL OF CRITICAL CARE, 2011, 26 (04) : 347 - 351
  • [3] Anti-Xa monitoring in critically ill patients with normal renal function on therapeutic enoxaparin
    Sargent, Kathleen M.
    Robbins, Adele
    Njoroge, Milka W.
    Donovan, Jennifer L.
    Tran, Maichi T.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 35 (03) : 404 - 404
  • [4] Anti-Xa levels in critically ill children receiving enoxaparin for venothromboembolism prophylaxis
    Marshall, Amanda M.
    Trussell, Taylor M.
    Yee, Addison M.
    Malone, Mathew P.
    [J]. THROMBOSIS RESEARCH, 2021, 203 : 117 - 120
  • [5] ANTI-XA MONITORING OF WEIGHT-BASED ENOXAPARIN FOR VTE PROPHYLAXIS IN CRITICALLY ILL TRAUMA PATIENTS
    Taylor, Ashley
    Huang, Ellen
    Waller, Jennifer
    White, Cassandra
    Robinson, Tim
    [J]. CRITICAL CARE MEDICINE, 2020, 48
  • [6] Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients
    Helviz, Yigal
    Dzigivker, Ilia
    Raveh-Brawer, David
    Hersch, Moshe
    Zevin, Shoshana
    Einav, Sharon
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2016, 18 (02): : 108 - 113
  • [7] No effect of norepinephrine dose on anti-Xa activity in critically ill patients
    Meenks, Sjoerd D.
    Foudraine, Norbert A.
    Broen, Kelly
    le Noble, Jos L. M. L.
    Janssen, Paddy K. C.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (04) : 223 - 229
  • [8] Anti-Xa stability of diluted enoxaparin for use in pediatrics
    Dager, WE
    Gosselin, RC
    King, JH
    Christensen, CL
    Owings, JT
    Larkin, EC
    [J]. ANNALS OF PHARMACOTHERAPY, 2004, 38 (04) : 569 - 573
  • [9] Anti-Xa levels in critically ill patients receiving dalteparin for thromboprophylaxis.
    McDonald, E
    Dale, C
    Pleasance, S
    McNeill, A
    Harvey, J
    Wynne, C
    Duffett, M
    Provost, L
    Rioux, A
    LaRouche, G
    Davidson, C
    Watpool, I
    McCardle, T
    Foxall, J
    Bouwers, K
    Lewis, MJ
    Zytaruk, N
    Griffith, L
    Crowther, M
    Cook, D
    [J]. BLOOD, 2004, 104 (11) : 105B - 105B
  • [10] Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
    Mohamed, Adham
    Shemanski, Shelby M.
    Saad, Mohamed O.
    Ploetz, Jeannette
    Haines, Michelle M.
    Schlachter, Andrew B.
    Hamarshi, Majdi S.
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
12345